Medtronic warning letter
This article was originally published in The Gray Sheet
Executive SummaryFirm's Synchromed II and MiniMed Paradigm insulin pumps are subject to a June 1 FDA warning letter. During a Nov. 12-Dec. 15, 2008, inspection of Medtronic's Puerto Rico manufacturing facility, FDA identified quality system violations related to manufacture of the Synchromed devices and medical device reporting violations related to the Paradigm pumps. For example, Synchromed pumps were distributed and implanted in patients without being filled with a necessary propellant, but the firm took nearly two years to conduct a recall. In addition, Medtronic failed to report device-related serious injuries to FDA in a timely manner, the agency charges
You may also be interested in...
Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.